Business & Finance

Bacterio-Therapeutics company closes financing, announces new board member

Published in Gene Therapy Weekly, January 20th, 2005

Osel, Inc., closed a private round of financing, completed the in-clinic portion of a phase I clinical trial for their first product, LACTIN-V, for the treatment of recurrent bacterial vaginosis, and announced the appointment of Michael Cannon as a new board member following

The conclusion of the phase I clinical trial of LACTIN-V for recurrent bacterial vaginosis (RBV) represents a significant milestone for Osel. The product is also midway through a second phase I trial for recurrent urinary tract infection (RUTI) under the direction of Dr. Walter Stamm, MD, professor, medicine/infectious diseases, at the University of Washington, Seattle, Washington. Osel plans to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-01-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry